Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl) - 1-{6-[4-(4-ethyl-piperazin-1-yl)-phenyla mino] -pyrimidin-4-yl}-1-methyl-urea and salts thereof.

Details for Australian Patent Application No. 2010328391 (hide)

Owner Novartis AG

Inventors Berghausen, Joerg; Kapa, Prasad Koteswara; McKenna, Joseph; Slade, Joel; Wu, Raeann; Du, Zhengming

Agent Davies Collison Cave

Pub. Number AU-A-2010328391

PCT Pub. Number WO2011/071821

Priority 61/267,155 07.12.09 US

Filing date 6 December 2010

Wipo publication date 16 June 2011

International Classifications

C07D 239/48 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

7 June 2012 PCT application entered the National Phase

  PCT publication WO2011/071821 Priority application(s): WO2011/071821

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010328400-Fluid flow control device

2010328375-4-methylpyrazole formulations